NeuBase Therapeutics Statistics
Total Valuation
NBSE has a market cap or net worth of $1.63 million. The enterprise value is -$5.61 million.
| Market Cap | 1.63M |
| Enterprise Value | -5.61M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NBSE has 3.75 million shares outstanding. The number of shares has increased by 69.76% in one year.
| Shares Outstanding | 3.75M |
| Shares Change (YoY) | +69.76% |
| Shares Change (QoQ) | +62.92% |
| Owned by Insiders (%) | 13.38% |
| Owned by Institutions (%) | 12.68% |
| Float | 3.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.18 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.87, with a Debt / Equity ratio of 0.58.
| Current Ratio | 2.87 |
| Quick Ratio | n/a |
| Debt / Equity | 0.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,704.96 |
Financial Efficiency
Return on equity (ROE) is -103.50% and return on invested capital (ROIC) is -105.49%.
| Return on Equity (ROE) | -103.50% |
| Return on Assets (ROA) | -62.40% |
| Return on Capital (ROIC) | -105.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$371,083 |
| Employee Count | 37 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.90% in the last 52 weeks. The beta is 0.96, so NBSE's price volatility has been similar to the market average.
| Beta (1Y) | 0.96 |
| 52-Week Price Change | -82.90% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.83 |
| Relative Strength Index (RSI) | 38.87 |
| Average Volume (30 Days) | 239,859 |
Short Selling Information
The latest short interest is 149,120, so 3.97% of the outstanding shares have been sold short.
| Short Interest | 149,120 |
| Short Previous Month | 80,453 |
| Short % of Shares Out | 3.97% |
| Short % of Float | 4.52% |
| Short Ratio (days to cover) | 0.60 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.27M |
| Pretax Income | -13.73M |
| Net Income | -13.73M |
| EBITDA | -12.55M |
| EBIT | -13.72M |
| Earnings Per Share (EPS) | -$7.70 |
Balance Sheet
The company has $12.57 million in cash and $5.34 million in debt, giving a net cash position of $7.24 million or $1.93 per share.
| Cash & Cash Equivalents | 12.57M |
| Total Debt | 5.34M |
| Net Cash | 7.24M |
| Net Cash Per Share | $1.93 |
| Equity / Book Value | 9.14M |
| Book Value Per Share | 2.44 |
| Working Capital | 8.70M |
Cash Flow
In the last 12 months, operating cash flow was -$14.78 million and capital expenditures -$54,791, giving a free cash flow of -$14.84 million.
| Operating Cash Flow | -14.78M |
| Capital Expenditures | -54,791 |
| Free Cash Flow | -14.84M |
| FCF Per Share | -$5.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NBSE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -69.76% |
| Shareholder Yield | -69.76% |
| Earnings Yield | -843.27% |
| FCF Yield | -911.25% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 15, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jun 15, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |